Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 28.82% is 111% above its 5-year average of 13.68%, near the high end of its 5-year range (0.00%–30.82%).
As of the fiscal period ended Wednesday, December 31, 2025. 22.61% above its 12-month average of 23.51%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
28.82%
RETURN ON EQUITY (ROE) AVG TTM
23.51%
RETURN ON EQUITY (ROE) AVG 3Y
17.50%
RETURN ON EQUITY (ROE) AVG 5Y
13.68%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.61%
CURRENT VS 3Y AVG
+64.71%
CURRENT VS 5Y AVG
+110.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+164.65%
vs the sector median at left
Solventum Corporation
Market Cap
$13.51B
Return on Equity (ROE)
28.82%
TTM Avg
23.51%
3Y Avg
17.50%
5Y Avg
13.68%
Market Cap
$13.71B
Return on Equity (ROE)
2.86%
TTM Avg
4.70%
3Y Avg
4.67%
5Y Avg
11.22%
Market Cap
$12.32B
Return on Equity (ROE)
3.35%
TTM Avg
3.59%
3Y Avg
3.35%
5Y Avg
7.68%
Market Cap
$11.96B
Return on Equity (ROE)
10.36%
TTM Avg
10.54%
3Y Avg
10.84%
5Y Avg
19.93%
Market Cap
$15.11B
Return on Equity (ROE)
-114.70%
TTM Avg
329.18%
3Y Avg
200.63%
5Y Avg
164.66%
Market Cap
$11.57B
Return on Equity (ROE)
-18.17%
TTM Avg
-12.46%
3Y Avg
-8.76%
5Y Avg
-1.37%
Market Cap
$11.31B
Return on Equity (ROE)
23.25%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$11.21B
Return on Equity (ROE)
5.25%
TTM Avg
5.98%
3Y Avg
10.62%
5Y Avg
11.34%
Market Cap
$10.91B
Return on Equity (ROE)
-6.28%
TTM Avg
-2.13%
3Y Avg
6.32%
5Y Avg
9.65%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $13.51B | 28.82% | 23.51% | 17.50% | 13.68% |
| The Cooper Companies, Inc. (COO)vs › | $13.71B | 2.86% | 4.70% | 4.67% | 11.22% |
| Revvity, Inc. (RVTY)vs › | $12.32B | 3.35% | 3.59% | 3.35% | 7.68% |
| Align Technology, Inc. (ALGN)vs › | $11.96B | 10.36% | 10.54% | 10.84% | 19.93% |
| DaVita Inc. (DVA)vs › | $15.11B | -114.70% | 329.18% | 200.63% | 164.66% |
| Baxter International Inc. (BAX)vs › | $11.57B | -18.17% | -12.46% | -8.76% | -1.37% |
| Insulet Corp. (PODD)vs › | $11.31B | 23.25% | 25.41% | 19.99% | 14.02% |
| Bio-Techne Corporation (TECH)vs › | $11.21B | 5.25% | 5.98% | 10.62% | 11.34% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.91B | -6.28% | -2.13% | 6.32% | 9.65% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
ROE
28.8%
ROA
10.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 30.82% |
| 2024-12-31 | 16.19% |
| 2023-12-31 | 11.54% |
| 2022-12-31 | 11.44% |
| 2021-12-31 | 12.11% |
| 2020-12-31 | 0.00% |
